Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page
- Check7 days agoChange DetectedRevision: v3.5.0 has been added and revision v3.4.3 has been removed.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check29 days agoNo Change Detected
- Check50 days agoChange DetectedRevision: v3.4.2 was added and the prior funding notice (v3.4.1) was removed; there are no changes to study content, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check57 days agoChange DetectedA government funding/status notice was added to the page footer and the site revision updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check64 days agoChange DetectedAdded a glossary toggle. Made minor wording/casing updates to update log and footer metadata, and updated the page revision.SummaryDifference0.2%

- Check100 days agoChange DetectedAdded a Locations section with the Washington site listed. The footer revision note was updated to v3.3.3 and the HHS Vulnerability Disclosure and Washington Locations entries were removed.SummaryDifference0.2%

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.